Abstract 400P
Background
Breast cancer is the leading killer of female cancer patient. Lung cancer became the second affecting cancer (12%) but the main killer (25%) in female cancer patient. (Cancer fact and Figures 2017” report published by American Cancer Society) and odd of getting lung cancer are 1 in 17. In Bangladesh, the status and features of female lung cancer is not clear. In western country, female are more prone to lung cancer due to some risk factor like smoking, alcohol, exposure of radon etc than Bangladesh. We tried to find out the socio-demographic status and clinical features of lung cancer of female in Bangladesh.
Methods
This was a descriptive comparative observational study on 2396 female cancer patients reached at Outpatient of Medical oncology department of National Institute of cancer Research and Hospital, Mohakhali, Bangladesh from January 2018 to December 2018. Patients were selected purposive sampling method.
Results
Total number of 2396 female patients were included in this study. The average age of female lung cancer patient was 56.12 years and average weight was 45.32kg. We had found 336 lung cancer patients (14%) among the 2396 female cancer patient. 58% were adenocarcinoma, 26% were Squamous Cell, 7% small cell variety with undifferentiated and others like Sarcoma, mesothelioma etc were 9%. Most of the patients were illiterate (59%) and 79% patient were poor or below average economically. 42% female patient didn’t have any habitual problem. 46.82%% patients had the battle nut/ Jarda, 7.65% were smoker, about 10% had more than one habitual issue. At the time of presentation none of the had ECOG 0, patients had performance status O, most of the patient’s performance status (ECOG) were 1 (58%) ECOG2 were 27%. 39% patient had comorbidity, among them most frequent comorbidity was Hypertension which was 39% and second was DM (33%) and 20% patient having more than one comorbidity.
Conclusions
The percentage of female lung cancer in Bangladesh is pretty high among female cancer patient. female are most vulnerable group in rural area as well as they need special attention. Moreover, female lung cancer with other comorbidities makes the treatment more complicated for the cancer physician as well as brings the worst outcome. So, female lung cancer management should be personalized and comprehensive.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
Presenter: Jinliang Wang
Session: Poster display session
Resources:
Abstract
525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma
Presenter: Akito Fukuda
Session: Poster display session
Resources:
Abstract
524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
Presenter: Heekyung Ahn
Session: Poster display session
Resources:
Abstract
513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed
Presenter: Shingo Kitagawa
Session: Poster display session
Resources:
Abstract
493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
Presenter: Sarita Shrivastva
Session: Poster display session
Resources:
Abstract
494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
517P - High BRCA1 expression is independently correlated with decreased overall survival in lung adenocarcinoma: Evidence from meta and bioinformatics analyses
Presenter: Fengzhu Guo
Session: Poster display session
Resources:
Abstract